glp 1 podcast The Holistic GLP-1 with Elizabeth McGann S6.E8: My Life on GLP1:

When weight data is transmitted to healthcare providers, they can analyze trends, identify plateaus, and make informed recommendations without waiting for in-person appointments

SGLT-2 inhibitors and GLP-1RA should, therefore, be considered evidence-based treatments for patients with type 2 diabetes after metformin

Lilly reportedly plans to seek FDA approval for this use and if approved, the drug would be the first pharmaceutical treatment on the market for sleep apnea

In 2024 semaglutide (Wegovy) became the first weight loss drug to also be approved for the reduction of risk of serious cardiovascular events in patients with cardiovascular (CV) disease and obesity and overweight

O, open

Conversely, higher body weight may require the full dose escalation to achieve meaningful results